Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tucatinib Combination for Leptomeningeal Metastases in HER2+ Breast Cancer
NCT03501979Phase 2Terminated
- Sponsor
- University of Alabama at Birmingham
- Start
- Feb 2019
- Primary completion
- Jun 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of tucatinib in HER2-positive breast cancer and leptomeningeal metastases (LM), sponsored by University of Alabama at Birmingham. Primary endpoint: Length of Subject Survival After Starting Study Treatment at 2 years. Started Feb 2019; status: terminated.
02
Drugs
tucatinib
03
Conditions
HER2-positive breast cancerleptomeningeal metastases (LM)
Beyond the preview
Go deeper on NCT03501979.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03501979.